<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04538560</url>
  </required_header>
  <id_info>
    <org_study_id>P2020002</org_study_id>
    <nct_id>NCT04538560</nct_id>
  </id_info>
  <brief_title>Preimplantation Genetic Testing for Aneuploidy of Polar Bodies</brief_title>
  <official_title>Preimplantation Genetic Testing for Aneuploidy by Next-generation Sequencing of Polar Bodies in Advanced Maternal Age With Poor Ovarian Responders: a Randomized Clinical Trial (Preliminary Experiments)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reproductive &amp; Genetic Hospital of CITIC-Xiangya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reproductive &amp; Genetic Hospital of CITIC-Xiangya</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to randomly group the patients with advanced maternal age and poor ovarian&#xD;
      response, and the study group will undergo polar body biopsy, and the next-generation&#xD;
      sequencing(NGS) technology will be used to evaluate the polar body euploidy and then predict&#xD;
      the euploidy of the oocyte. Embryo transfer priority according to the NGS test results and&#xD;
      morphological scores. In the control group undergo routine culture and the transfer priority&#xD;
      is determined according to the morphological score only. The transfer of frozen embryos at&#xD;
      the cleavage or blastocyst stage was permitted. Cumulative live birth rate, miscarriage rate&#xD;
      and time required to obtain a live birth up to two ovulatory cycles in a year.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative live birth rate</measure>
    <time_frame>22 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>abortion rate</measure>
    <time_frame>22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time required to obtained a live birth</measure>
    <time_frame>22 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Subfertility</condition>
  <arm_group>
    <arm_group_label>Polar body biopsy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study group will undergo polar body biopsy, and the NGS technology will be used to evaluate the polar body euploidy and then predict the euploidy of the oocyte. Embryo transfer priority according to the NGS test results and morphological scores.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will undergo routine culture and the transfer priority is determined according to the morphological score only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>polar body biopsy</intervention_name>
    <description>Undergo polar body biopsy, and the NGS technology will be used to evaluate the polar body euploidy and then predict the euploidy of the oocyte. Embryo transfer priority according to the NGS test results and morphological scores.</description>
    <arm_group_label>Polar body biopsy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients between their 36th and 42st birthdays;&#xD;
&#xD;
          -  absence of any type of genetic abnormality in the patient's personal and family&#xD;
             history;&#xD;
&#xD;
          -  MⅡ oocytes: 2-9 .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  treatment involving donor oocytes;&#xD;
&#xD;
          -  any type of genetic abnormality or family history of genetic abnormality in subject or&#xD;
             partner;&#xD;
&#xD;
          -  with assisted reproductive technology and pregnancy contraindications and with&#xD;
             diseases that have a definite effect on pregnancy;&#xD;
&#xD;
          -  poor embryo quality in previous cycles;&#xD;
&#xD;
          -  Preimplantation genetic testing for aneuploidy(PGT-A) cycles;&#xD;
&#xD;
          -  MⅡ oocytes ≥10 or ≤ 1;&#xD;
&#xD;
          -  three or more previous failed IVF or Intracytoplasmic sperm injection(ICSI) cycles.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>36 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Reproductive and Genetic Hospital of Citic-xiangya</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiaojuan Wang, Doc</last_name>
      <phone>+86-731-82355100</phone>
      <email>646829625@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2020</study_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>poor ovarian respond，</keyword>
  <keyword>advanced age</keyword>
  <keyword>Preimplantation Genetic Testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Aneuploidy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

